You are here

Continuing Education Credit

Incorporating Omalizumab into Asthma Treatment Guidelines: Consensus Panel Recommendations

Lanny J. Rosenwasser, MD, FAAAAI, David B. Nash, MD, MBA, FACP, and members of the Consensus Panel
PDF version: 
A new drug, omalizumab (Xolair™), appears to be effective in overcoming the difficulties in treating persistent and moderate-to-severe asthma.